MARCH BDI-40 UP 11%, ASX200 UP 0.1% - PRANA UP 60.5%, CHEMGENEX 52.5%, ANTISENSE 50%, BIONOMICS 41%
April 3rd 2011 23:27
Biotech Daily
Friday April 1, 2011
Daily news on ASX-listed biotechnology companies
Friday April 1, 2011
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTECH DAILY’S TOP 40 INDEX
The Biotech Daily Top 40 Index (BDI-40) returned to its stellar trajectory following February’s 3.4 percent stumble, up 10.7 percent in March compared to the S&P ASX200 up 0.14 percent.
The BDI-40 was up 52.9 percent for the year to March 31, 2011 compared to the ASX200 falling 0.8 percent and the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) falling 6.8 percent for the year.
The Big Caps fell 0.13 percent in March with Cochlear up 7.3 percent to $4,709 million, while CSL slipped 0.28 percent to $19,337 million and Resmed lost 6.4 percent to $4,466 million.
The sector was buoyed by Cephalon’s bid for Chemgenex lifting its market capitalization 52.5 percent from $120 million to close the month at $183 million and Bionomics excellent BNC210 results pushing its price up 40.7 percent to a market capitalization of $166 million.
But the best percentage improvement for the month was Prana’s $23 million or 60.5 percent rise to $61 million, while the fifth best, Mesoblast, was up 39.4 percent, which added $572 million to its market capitalization taking it to $2,023 million. Antisense was up 50 percent to $12 million followed by Patrys up 26.1 percent to $29 million, Starpharma (21.5%) to $305 million, Psivida (13.7%) to $83 million and Cellestis (11.2%) to $287 million.
Optiscan had the deepest percentage fall, down 25 percent to $6 million, followed by Benitec losing 22.2 percent to $14 million; Genera and Living cell both fell 20 percent to $16 million and $24 million respectively; Clinuvel fell 17.9 percent to $55 million, Virax fell 16.7 percent to $5 million’ with Compumedics down 14.3 percent and Acrux easing 11.5 percent to $502 million.
Biotech companies raised $24.406 million in March.
See charts below.
BDI-40 v ASX200 Jul 1, 2006 to Mar 31, 2011
BDI-40 ($m) v S&P ASX200 2010-2011
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 17 |
| Vote |
Add To: 
subscribe to this blog